Upstream / Downstream

Explore pathways related to this product.

Important Ordering Details

Custom Ordering Details: This product is assembled upon order. Please allow up to three weeks for your product to be processed

Pricing & Additional Information

To learn more about our Blocking Peptides, including pricing, please answer a few questions.

Pricing & Additional Information  

Questions?

Find answers on our FAQs page.

ANSWERS  

Visit PhosphoSitePlus®

PTM information and tools available.

LEARN MORE

Immunohistochemical analysis of paraffin-embedded human breast carcinoma, using p44/42 MAPK (Erk1/2) (L34F12) Mouse mAb #4696 in the presence of control peptide (left) or p44/42 MAPK (Erk1/2) Blocking Peptide (#4696 Specific) (right).

Learn more about how we got this image
Image

Product Description

This peptide is used to specifically block p44/42 MAPK (Erk1/2) (L34F12) Mouse mAb #4696 reactivity.


Quality Control

The quality of the peptide was evaluated by reversed-phase HPLC and by mass spectrometry. The peptide blocks p44/42 MAPK (Erk1/2) (L34F12) Mouse mAb #4696 signal in immunohistochemistry.

Product Usage Information

Use as a blocking reagent to evaluate the specificity of antibody reactivity in western immunoblotting and immunohistochemistry protocols. For immunohistochemistry, add twice the volume of peptide as volume of antibody used in 100 μl total volume. Incubate for a minimum of 30 minutes prior to adding the entire volume to the slide. Recommended antibody dilutions can be found on the product data sheet.


Storage: Supplied in 20 mM potassium phosphate (pH 7.0), 50 mM NaCl, 0.1 mM EDTA, 1 mg/ml BSA and 5% glycerol. Store at –20°C.

Mitogen-activated protein kinases (MAPKs) are a widely conserved family of serine/threonine protein kinases involved in many cellular programs, such as cell proliferation, differentiation, motility, and death. The p44/42 MAPK (Erk1/2) signaling pathway can be activated in response to a diverse range of extracellular stimuli including mitogens, growth factors, and cytokines (1-3), and research investigators consider it an important target in the diagnosis and treatment of cancer (4). Upon stimulation, a sequential three-part protein kinase cascade is initiated, consisting of a MAP kinase kinase kinase (MAPKKK or MAP3K), a MAP kinase kinase (MAPKK or MAP2K), and a MAP kinase (MAPK). Multiple p44/42 MAP3Ks have been identified, including members of the Raf family, as well as Mos and Tpl2/COT. MEK1 and MEK2 are the primary MAPKKs in this pathway (5,6). MEK1 and MEK2 activate p44 and p42 through phosphorylation of activation loop residues Thr202/Tyr204 and Thr185/Tyr187, respectively. Several downstream targets of p44/42 have been identified, including p90RSK (7) and the transcription factor Elk-1 (8,9). p44/42 are negatively regulated by a family of dual-specificity (Thr/Tyr) MAPK phosphatases, known as DUSPs or MKPs (10), along with MEK inhibitors, such as U0126 and PD98059.


1.  Roux, P.P. and Blenis, J. (2004) Microbiol Mol Biol Rev 68, 320-44.

2.  Baccarini, M. (2005) FEBS Lett 579, 3271-7.

3.  Meloche, S. and Pouysségur, J. (2007) Oncogene 26, 3227-39.

4.  Roberts, P.J. and Der, C.J. (2007) Oncogene 26, 3291-310.

5.  Rubinfeld, H. and Seger, R. (2005) Mol Biotechnol 31, 151-74.

6.  Murphy, L.O. and Blenis, J. (2006) Trends Biochem Sci 31, 268-75.

7.  Dalby, K.N. et al. (1998) J Biol Chem 273, 1496-505.

8.  Marais, R. et al. (1993) Cell 73, 381-93.

9.  Kortenjann, M. et al. (1994) Mol Cell Biol 14, 4815-24.

10.  Owens, D.M. and Keyse, S.M. (2007) Oncogene 26, 3203-13.


Entrez-Gene Id 5595, 5594
Swiss-Prot Acc. P27361, P28482


For Research Use Only. Not For Use In Diagnostic Procedures.
Cell Signaling Technology® is a trademark of Cell Signaling Technology, Inc.